The NCCN Guidelines for Palliative Care provide interdisciplinary recommendations on palliative care for patients with cancer. The NCCN Guidelines are intended to provide guidance to the primary oncology team on the integration of palliative care into oncology. The NCCN Palliative Care Panel's recommendations seek to ensure that each patient experiences the best quality of life possible throughout the illness trajectory. Accordingly, the NCCN Guidelines outline best practices for screening, assessment, palliative care interventions, reassessment, and after-death care.

  • 1.

    Berger A, Portenoy R, Weissman D, eds. Practice and Principles of Supportive Oncology. Philadelphia: Lippincott-Raven; 1998.

  • 2.

    Doyle D, Hanks G, MacDonald Ne, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford University; 1998.

  • 3.

    Emanuel L, von Gunten C, FD F, eds. The Education for Physicians on End-of-Life Care (EPEC) Curriculum. Princeton: The Robert Wood Johnson Foundation; 1999.

    • Search Google Scholar
    • Export Citation
  • 4.

    Cleeland CS, Zhao F, Chang VT. The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 2013;119:43334340.

    • Search Google Scholar
    • Export Citation
  • 5.

    Smith TJ, Temin S, Alesi ER. American Society of Clinical Oncology Provisional Clinical Opinion: the integration of palliative care into standard oncology care. J Clin Oncol 2012;30:880887.

    • Search Google Scholar
    • Export Citation
  • 6.

    Temel JS, Greer JA, Muzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733742.

    • Search Google Scholar
    • Export Citation
  • 7.

    Diver E, O'Connor O, Garrett L. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol 2013;129:332335.

    • Search Google Scholar
    • Export Citation
  • 8.

    Richards DM, Tanikella R, Arora G. Percutaneous endoscopic gastrostomy in cancer patients: predictors of 30-day complications, 30-day mortality, and overall mortality. Dig Dis Sci 2013;58:768776.

    • Search Google Scholar
    • Export Citation
  • 9.

    Salpeter SR, Malter DS, Luo EJ. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012;15:175185.

    • Search Google Scholar
    • Export Citation
  • 10.

    Communicating with Patients on Health Care Evidence. Institute of Medicine; 2012. Available at: http://www.iom.edu/Global/Perspectives/2012/Evidence.aspx. Accessed May 17, 2013.

    • Search Google Scholar
    • Export Citation
  • 11.

    Novelli WD, Halvorson GC, Santa J. Recognizing an Opinion: Findings From the IOM Evidence Communication Innovation Collaborative JAMA 2012;308:15311532.

    • Search Google Scholar
    • Export Citation
  • 12.

    Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician 2006;73:485492.

  • 13.

    Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004;31 Suppl 1:S149161.

    • Search Google Scholar
    • Export Citation
  • 14.

    Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005;55:300318; quiz 323–305.

  • 15.

    Prommer E. Guidelines for the Use of Palliative Chemotherapy. AAHPM Bulletin 2004;5:213.

  • 16.

    Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10 Suppl 3:4958.

  • 17.

    Brown J, Thorpe H, Napp V. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005;23:74177427.

    • Search Google Scholar
    • Export Citation
  • 18.

    Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005;128:39753984.

    • Search Google Scholar
    • Export Citation
  • 19.

    Chen AB, Cronin A, Weeks JC. Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol 2013;31:558564.

    • Search Google Scholar
    • Export Citation
  • 20.

    Zafar SY, Malin JL, Grambow SC. Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. Cancer 2013;119:854862.

    • Search Google Scholar
    • Export Citation
  • 21.

    Higginson IJ, Finlay IG, Goodwin DM. Is there evidence that palliative care teams alter end-of-life experiences of patients and their caregivers? J Pain Symptom Manage 2003;25:150168.

    • Search Google Scholar
    • Export Citation
  • 22.

    Kinzbrunner BM. Hospice: what to do when anti-cancer therapy is no longer appropriate, effective, or desired. Semin Oncol 1994;21:792798.

    • Search Google Scholar
    • Export Citation
  • 23.

    Trajkovic-Vidakovic M, de Graeff A, Voest EE, Teunissen SC. Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol 2012;84:130148.

    • Search Google Scholar
    • Export Citation
  • 24.

    Yennurajalingam S, Kwon JH, Urbauer DL. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. Palliat Support Care 2013;11:473480.

    • Search Google Scholar
    • Export Citation
  • 25.

    Van Lancker A, Velghe A, Van Hecke A. Prevalence of symptoms in older cancer patients receiving palliative care: a systematic review and meta-analysis. J Pain Symptom Manage 2014;47:90104.

    • Search Google Scholar
    • Export Citation
  • 26.

    Ferrell B, Levy MH, Paice J. Managing pain from advanced cancer in the palliative care setting. Clin J Oncol Nurs 2008;12:575581.

  • 27.

    Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006;7:241249.

    • Search Google Scholar
    • Export Citation
  • 28.

    Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159:321340.

    • Search Google Scholar
    • Export Citation
  • 29.

    DeCamp MM Jr., Mentzer SJ, Swanson SJ, Sugarbaker DJ. Malignant effusive disease of the pleura and pericardium. Chest 1997;112:291S295S.

  • 30.

    Dy SM, Lorenz KA, Naeim A. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 2008;26:38863895.

    • Search Google Scholar
    • Export Citation
  • 31.

    Swanson N, Mirza I, Wijesinghe N, Devlin G. Primary percutaneous balloon pericardiotomy for malignant pericardial effusion. Catheter Cardiovasc Interv 2008;71:504507.

    • Search Google Scholar
    • Export Citation
  • 32.

    Xue D, Abernethy AP. Management of dyspnea in advanced lung cancer: recent data and emerging concepts. Curr Opin Support Palliat Care 2010;4:8591.

    • Search Google Scholar
    • Export Citation
  • 33.

    Dy SM, Apostol CC. Evidence-based approaches to other symptoms in advanced cancer. Cancer J 2010;16:507513.

  • 34.

    Ben-Aharon I, Gafter-Gvili A, Paul M. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26:23962404.

    • Search Google Scholar
    • Export Citation
  • 35.

    Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. Acta Oncol 2012;51:9961008.

    • Search Google Scholar
    • Export Citation
  • 36.

    Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 2008;11:204216.

    • Search Google Scholar
    • Export Citation
  • 37.

    Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of Moderate-to-Severe Dyspnea in Hospitalized Patients Receiving Palliative Care. J Pain Symptom Manage 2012.

    • Search Google Scholar
    • Export Citation
  • 38.

    Jennings AL, Davies AN, Higgins JP. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939944.

  • 39.

    Simon ST, Higginson IJ, Booth S. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010:CD007354.

    • Search Google Scholar
    • Export Citation
  • 40.

    Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002;23:157160.

    • Search Google Scholar
    • Export Citation
  • 41.

    Smith TJ, Coyne P, French W. Failure to accrue to a study of nebulized fentanyl for dyspnea: lessons learned. J Palliat Med 2009;12:771772.

  • 42.

    Simon ST, Koskeroglu P, Gaertner J, Voltz R. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage 2013;46:874886.

    • Search Google Scholar
    • Export Citation
  • 43.

    Hui D, Xu A, Frisbee-Hume S. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage 2014;47:209217.

    • Search Google Scholar
    • Export Citation
  • 44.

    Jensen D, Alsuhail A, Viola R. Inhaled Fentanyl Citrate Improves Exercise Endurance During High-Intensity Constant Work Rate Cycle Exercise in Chronic Obstructive Pulmonary Disease. J Pain Symptom Manage 2011.

    • Search Google Scholar
    • Export Citation
  • 45.

    Kawabata M, Kaneishi K. Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study. Am J Hosp Palliat Care 2013;30:305311.

    • Search Google Scholar
    • Export Citation
  • 46.

    Back IN, Jenkins K, Blower A, Beckhelling J. A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med 2001;15:329336.

    • Search Google Scholar
    • Export Citation
  • 47.

    Davis MP, Furste A. Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction. J Pain Symptom Manage 1999;18:153154.

    • Search Google Scholar
    • Export Citation
  • 48.

    Hughes A, Wilcock A, Corcoran R. Audit of three antimuscarinic drugs for managing retained secretions. Palliat Med 2000;14:221222.

  • 49.

    Wildiers H, Menten J. Death rattle: prevalence, prevention and treatment. J Pain Symptom Manage 2002;23:310317.

  • 50.

    Wildiers H, Dhaenekint C, Demeulenaere P. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage 2009;38:124133.

    • Search Google Scholar
    • Export Citation
  • 51.

    Grum DF, Osborne LR. Central anticholinergic syndrome following glycopyrrolate. Anesthesiology 1991;74:191193.

  • 52.

    Wingard DW. Glycopyrrolate and the central anticholinergic syndrome. Anesthesiology 1991;75:11251126.

  • 53.

    Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia 1983;38:11951204.

  • 54.

    Death Rattle and Oral Secretions, 2nd ed. End of Life / Palliative Education Resource Center (EPERC); Available at: http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_109.htm. Accessed May 20, 2013.

    • Search Google Scholar
    • Export Citation
  • 55.

    Galbraith S, Fagan P, Perkins P. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010;39:831838.

    • Search Google Scholar
    • Export Citation
  • 56.

    Abernethy AP, McDonald CF, Frith PA. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010;376:784793.

    • Search Google Scholar
    • Export Citation
  • 57.

    Nava S, Ferrer M, Esquinas A. Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial. Lancet Oncol 2013;14:219227.

    • Search Google Scholar
    • Export Citation
  • 58.

    Hui D, Morgado M, Chisholm G. High-flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase II randomized trial. J Pain Symptom Manage 2013;46:463473.

    • Search Google Scholar
    • Export Citation
  • 59.

    Kumar NB, Kazi A, Smith T. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010;11:107117.

    • Search Google Scholar
    • Export Citation
  • 60.

    Laviano A, Meguid MM, Inui A. Therapy insight: Cancer anorexia-cachexia syndrome: when all you can eat is yourself. Nat Clin Pract Oncol 2005;2:158165.

    • Search Google Scholar
    • Export Citation
  • 61.

    Oberholzer R, Hopkinson JB, Baumann K. Psychosocial Effects of Cancer Cachexia: A Systematic Literature Search and Qualitative Analysis. J Pain Symptom Manage 2012.

    • Search Google Scholar
    • Export Citation
  • 62.

    Martin L, Birdsell L, Macdonald N. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:15391547.

    • Search Google Scholar
    • Export Citation
  • 63.

    Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27:360369.

    • Search Google Scholar
    • Export Citation
  • 64.

    Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013;3:CD004310.

    • Search Google Scholar
    • Export Citation
  • 65.

    Yavuzsen T, Davis MP, Walsh D. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005;23:85008511.

    • Search Google Scholar
    • Export Citation
  • 66.

    Miller S, McNutt L, McCann MA, McCorry N. Use of corticosteroids for anorexia in palliative medicine: a systematic review. J Palliat Med 2014;17:482485.

    • Search Google Scholar
    • Export Citation
  • 67.

    Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010;18:951956.

    • Search Google Scholar
    • Export Citation
  • 68.

    Mantovani G, Maccio A, Madeddu C. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200211.

    • Search Google Scholar
    • Export Citation
  • 69.

    Maccio A, Madeddu C, Gramignano G. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012;124:417425.

    • Search Google Scholar
    • Export Citation
  • 70.

    Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003;11:137143.

    • Search Google Scholar
    • Export Citation
  • 71.

    Strasser F, Luftner D, Possinger K. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:33943400.

    • Search Google Scholar
    • Export Citation
  • 72.

    Jatoi A, Windschitl HE, Loprinzi CL. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567573.

    • Search Google Scholar
    • Export Citation
  • 73.

    Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 2004;91:447452.

    • Search Google Scholar
    • Export Citation
  • 74.

    Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005;23:14311438.

    • Search Google Scholar
    • Export Citation
  • 75.

    Trentham K. Palliative Care. In: Marian M, Roberts S, eds. Clinical Nutrition for Oncology Patients. Sudbury, MA: Jones and Bartlett Publishers LLC; 2010.

    • Search Google Scholar
    • Export Citation
  • 76.

    Baldwin C, Spiro A, McGough C. Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial. J Hum Nutr Diet 2011;24:431440.

    • Search Google Scholar
    • Export Citation
  • 77.

    Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012;104:371385.

    • Search Google Scholar
    • Export Citation
  • 78.

    August DA, Huhmann MB. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 2009;33:472500.

    • Search Google Scholar
    • Export Citation
  • 79.

    McCann RM, Hall WJ, Groth-Juncker A. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA 1994;272:12631266.

    • Search Google Scholar
    • Export Citation
  • 80.

    Weiner RS, Kramer BS, Clamon GH. Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer. J Clin Oncol 1985;3:949957.

    • Search Google Scholar
    • Export Citation
  • 81.

    Winter SM. Terminal nutrition: framing the debate for the withdrawal of nutritional support in terminally ill patients. Am J Med 2000;109:723726.

    • Search Google Scholar
    • Export Citation
  • 82.

    Bruera E, Hui D, Dalal S. Parenteral hydration in patients with advanced cancer: a multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol 2013;31:111118.

    • Search Google Scholar
    • Export Citation
  • 83.

    Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;4:38.

  • 84.

    Shoemaker LK, Estfan B, Induru R, Walsh TD. Symptom management: an important part of cancer care. Cleve Clin J Med 2011;78:2534.

  • 85.

    Holt DW, Volans GN. Gastrointestinal symptoms of digoxin toxicity. Br Med J 1977;2:704.

  • 86.

    Hwang WJ, Tsai JJ. Acute phenytoin intoxication: causes, symptoms, misdiagnoses, and outcomes. Kaohsiung J Med Sci 2004;20:580585.

  • 87.

    Hardy JR, O'Shea A, White C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage 2010;40:111116.

    • Search Google Scholar
    • Export Citation
  • 88.

    Gralla RJ, Itri LM, Pisko SE. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905909.

    • Search Google Scholar
    • Export Citation
  • 89.

    Buzdar AU, Esparza L, Natale R. Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study. Am J Clin Oncol 1994;17:417421.

    • Search Google Scholar
    • Export Citation
  • 90.

    Tan L, Liu J, Liu X. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:131.

    • Search Google Scholar
    • Export Citation
  • 91.

    Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011;9:188195.

    • Search Google Scholar
    • Export Citation
  • 92.

    Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:11371141.

    • Search Google Scholar
    • Export Citation
  • 93.

    Marty M, Pouillart P, Scholl S. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-821.

    • Search Google Scholar
    • Export Citation
  • 94.

    Kris MG, Gralla RJ, Clark RA. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987;60:28162822.

    • Search Google Scholar
    • Export Citation
  • 95.

    Aapro MS, Plezia PM, Alberts DS. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984;2:466471.

    • Search Google Scholar
    • Export Citation
  • 96.

    Navari RM, Einhorn LH, Passik SD. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 2005;13:529534.

    • Search Google Scholar
    • Export Citation
  • 97.

    Herman TS, Einhorn LH, Jones SE. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979;300:12951297.

    • Search Google Scholar
    • Export Citation
  • 98.

    Morita T, Takigawa C, Onishi H. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. J Pain Symptom Manage 2005;30:96103.

    • Search Google Scholar
    • Export Citation
  • 99.

    Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 2007;5:19.

    • Search Google Scholar
    • Export Citation
  • 100.

    Mamtani R, Cimino A. A primer of complementary and alternative medicine and its relevance in the treatment of mental health problems. Psychiatr Q 2002;73:367381.

    • Search Google Scholar
    • Export Citation
  • 101.

    Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. Cancer J 2006;12:425431.

  • 102.

    Marchioro G, Azzarello G, Viviani F. Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology 2000;59:100104.

    • Search Google Scholar
    • Export Citation
  • 103.

    Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manage 2010;39:756767.

    • Search Google Scholar
    • Export Citation
  • 104.

    Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007;34:547565.

    • Search Google Scholar
    • Export Citation
  • 105.

    Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998;6:356364.

  • 106.

    Dhingra L, Shuk E, Grossman B. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med 2013;27:447456.

    • Search Google Scholar
    • Export Citation
  • 107.

    American Pain Socitey. Principles ofAnalgesic use in the treatment of acute pain and cancer pain (ed 5th). Glenview, IL: American Pain Society; 2003.

    • Search Google Scholar
    • Export Citation
  • 108.

    Candy B, Jones L, Larkin PJ. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev 2015;5:CD003448.

    • Search Google Scholar
    • Export Citation
  • 109.

    Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008;11:575581.

    • Search Google Scholar
    • Export Citation
  • 110.

    Portenoy RK, Thomas J, Moehl Boatwright ML. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35:458468.

    • Search Google Scholar
    • Export Citation
  • 111.

    Thomas J, Karver S, Cooney GA. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:23322343.

  • 112.

    Webster L, Chey WD, Tack J. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther 2014;40:771779.

    • Search Google Scholar
    • Export Citation
  • 113.

    Chey WD, Webster L, Sostek M. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370:23872396.

  • 114.

    Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol 2015;110:725732.

    • Search Google Scholar
    • Export Citation
  • 115.

    Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging 2008;3:357364.

  • 116.

    Chey WD, Lembo AJ, Lavins BJ. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:17021712.

    • Search Google Scholar
    • Export Citation
  • 117.

    Chang L, Lembo AJ, Lavins BJ. The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. Aliment Pharmacol Ther 2014;40:13021312.

    • Search Google Scholar
    • Export Citation
  • 118.

    Weinberg DS, Smalley W, Heidelbaugh JJ. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:11461148.

    • Search Google Scholar
    • Export Citation
  • 119.

    PDQ® Gastrointestinal Complications. Bethesda, MD: National Cancer Institute; Available at: http://cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional. Accessed March 17, 2015.

    • Search Google Scholar
    • Export Citation
  • 120.

    Benson AB 3rd, Ajani JA, Catalano RB. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:29182926.

    • Search Google Scholar
    • Export Citation
  • 121.

    Andreyev J, Ross P, Donnellan C. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 2014;15:e447460.

  • 122.

    Pessi MA, Zilembo N, Haspinger ER. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol 2014;90:165179.

  • 123.

    Francescutti V, Miller A, Satchidanand Y. Management of bowel obstruction in patients with stage IV cancer: predictors of outcome after surgery. Ann Surg Oncol 2013;20:707714.

    • Search Google Scholar
    • Export Citation
  • 124.

    Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000:CD001219.

    • Search Google Scholar
    • Export Citation
  • 125.

    Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage 2012;44:604607.

    • Search Google Scholar
    • Export Citation
  • 126.

    Porzio G, Aielli F, Verna L. Can malignant bowel obstruction in advanced cancer patients be treated at home? Support Care Cancer 2011;19:431433.

    • Search Google Scholar
    • Export Citation
  • 127.

    Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for reversing malignant bowel obstruction. J Pain Symptom Manage 2004;28:412416.

    • Search Google Scholar
    • Export Citation
  • 128.

    Zelek L, Laval G, Asselain B. Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis. J Clin Oncol 2013;31:25192520.

    • Search Google Scholar
    • Export Citation
  • 129.

    Berger J, Lester P, Rodrigues L. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide. Am J Hosp Palliat Care 2015.

    • Search Google Scholar
    • Export Citation
  • 130.

    Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage 2007;33:217223.

    • Search Google Scholar
    • Export Citation
  • 131.

    Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol 2012;83:388392.

  • 132.

    Currow DC, Clark K, Cartmill J. A multi-site, fixed dose, parallel arm, double-blind, placebo controlled, block randomised trial of the addition of infusional octreotide or placebo to regular ranitidine and dexamethasone for the evaluation of vomiting associated with bowel obstruction at the end of life. [Abstract]. 2012 ASCO Annual Meeting: American Society for Clinical Oncology; 2012:TPS9153. Available at: http://meetinglibrary.asco.org/content/101301-114.

    • Search Google Scholar
    • Export Citation
  • 133.

    Baron TH. Interventional palliative strategies for malignant bowel obstruction. Curr Oncol Rep 2009;11:293297.

  • 134.

    Brooksbank MA, Game PA, Ashby MA. Palliative venting gastrostomy in malignant intestinal obstruction. Palliat Med 2002;16:520526.

  • 135.

    Mucke M, Mochamat, Cuhls H. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015;5:CD006788.

    • Search Google Scholar
    • Export Citation
  • 136.

    Escalante CP, Meyers C, Reuben JM. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J 2014;20:814.

    • Search Google Scholar
    • Export Citation
  • 137.

    Gong S, Sheng P, Jin H. Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis. PLoS One 2014;9:e84391.

    • Search Google Scholar
    • Export Citation
  • 138.

    Moraska AR, Sood A, Dakhil SR. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010;28:36733679.

    • Search Google Scholar
    • Export Citation
  • 139.

    Hovey E, de Souza P, Marx G. Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. Support Care Cancer 2014;22:12331242.

    • Search Google Scholar
    • Export Citation
  • 140.

    Jean-Pierre P, Morrow GR, Roscoe JA. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 2010;116:35133520.

    • Search Google Scholar
    • Export Citation
  • 141.

    Palesh OG, Roscoe JA, Mustian KM. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010;28:292298.

    • Search Google Scholar
    • Export Citation
  • 142.

    Savard J, Ivers H, Villa J. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 2011;29:35803586.

  • 143.

    Palesh O, Aldridge-Gerry A, Ulusakarya A. Sleep disruption in breast cancer patients and survivors. J Natl Compr Canc Netw 2013;11:15231530.

    • Search Google Scholar
    • Export Citation
  • 144.

    Yennurajalingam S, Chisholm G, Palla SL. Self-reported sleep disturbance in patients with advanced cancer: Frequency, intensity, and factors associated with response to outpatient supportive care consultation: a preliminary report. Palliat Support Care 2013:19.

    • Search Google Scholar
    • Export Citation
  • 145.

    Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540545.

  • 146.

    Payne RJ, Hier MP, Kost KM. High prevalence of obstructive sleep apnea among patients with head and neck cancer. J Otolaryngol 2005;34:304311.

    • Search Google Scholar
    • Export Citation
  • 147.

    Stern TP, Auckley D. Obstructive sleep apnea following treatment of head and neck cancer. Ear Nose Throat J 2007;86:101103.

  • 148.

    Antonescu-Turcu A, Parthasarathy S. CPAP and bi-level PAP therapy: new and established roles. Respir Care 2010;55:12161229.

  • 149.

    Allen RP, Chen C, Garcia-Borreguero D. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014;370:621631.

  • 150.

    Bassetti CL, Bornatico F, Fuhr P. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly 2011;141:w13274.

    • Search Google Scholar
    • Export Citation
  • 151.

    Ferini-Strambi L, Aarskog D, Partinen M. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874881.

    • Search Google Scholar
    • Export Citation
  • 152.

    Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717723.

    • Search Google Scholar
    • Export Citation
  • 153.

    Manconi M, Ferri R, Zucconi M. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. Mov Disord 2011;26:892895.

    • Search Google Scholar
    • Export Citation
  • 154.

    Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938943.

    • Search Google Scholar
    • Export Citation
  • 155.

    Oertel WH, Stiasny-Kolster K, Bergtholdt B. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213219.

    • Search Google Scholar
    • Export Citation
  • 156.

    Trenkwalder C, Garcia-Borreguero D, Montagna P. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:9297.

    • Search Google Scholar
    • Export Citation
  • 157.

    Walters AS, Ondo WG, Dreykluft T. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:14141423.

    • Search Google Scholar
    • Export Citation
  • 158.

    Berger AM. Update on the state of the science: sleep-wake disturbances in adult patients with cancer. Oncol Nurs Forum 2009;36:E165177.

    • Search Google Scholar
    • Export Citation
  • 159.

    Harsora P, Kessmann J. Nonpharmacologic management of chronic insomnia. Am Fam Physician 2009;79:125130.

  • 160.

    Jungquist CR, O'Brien C, Matteson-Rusby S. The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain. Sleep Med 2010;11:302309.

    • Search Google Scholar
    • Export Citation
  • 161.

    Howell D, Oliver TK, Keller-Olaman S. Sleep disturbance in adults with cancer: a systematic review of evidence for best practices in assessment and management for clinical practice. Ann Oncol 2013.

    • Search Google Scholar
    • Export Citation
  • 162.

    Garland SN, Carlson LE, Stephens AJ. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol 2014;32:449457.

    • Search Google Scholar
    • Export Citation
  • 163.

    Kim SW, Shin IS, Kim JM. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci 2008;62:7583.

    • Search Google Scholar
    • Export Citation
  • 164.

    Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005;66 Suppl 2:913.

  • 165.

    US Food and Drug Administration. Zolpidem Containing Products: Drug Safety Communication: FDA Requires Lower Recommended Doses. 2013. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm334738.htm. Accessed March 3, 2014.

    • Search Google Scholar
    • Export Citation
  • 166.

    Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992;50:7577.

    • Search Google Scholar
    • Export Citation
  • 167.

    2011 Physicians' Desk Reference (ed 65). Montvale, NJ: PDR Network, LLC; 2010.

  • 168.

    Diagnostic and statistical manual of mental disorders (ed 4th). Washington, DC: American Psychiatric Association; 1994.

  • 169.

    Bush SH, Kanji S, Pereira JL. Treating an Established Episode of Delirium in Palliative Care: Expert Opinion and Review of the Current Evidence Base With Recommendations for Future Development. J Pain Symptom Manage 2014.

    • Search Google Scholar
    • Export Citation
  • 170.

    Irwin SA, Pirrello RD, Hirst JM. Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice. J Palliat Med 2013;16:423435.

    • Search Google Scholar
    • Export Citation
  • 171.

    Hosie A, Davidson PM, Agar M. Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: a systematic review. Palliat Med 2013;27:486498.

    • Search Google Scholar
    • Export Citation
  • 172.

    de la Cruz M, Fan J, Yennu S. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer 2015.

    • Search Google Scholar
    • Export Citation
  • 173.

    Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol 2012;30:12061214.

  • 174.

    Zimmerman KM, Salow M, Skarf LM. Increasing anticholinergic burden and delirium in palliative care inpatients. Palliat Med 2014;28:335341.

  • 175.

    Devlin JW, Roberts RJ, Fong JJ. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010;38:419427.

    • Search Google Scholar
    • Export Citation
  • 176.

    Grover S, Mattoo SK, Gupta N. Usefulness of Atypical Antipsychotics and Choline Esterase Inhibitors in Delirium: A Review. Pharmacopsychiatry 2011.

    • Search Google Scholar
    • Export Citation
  • 177.

    Maher AR, Maglione M, Bagley S. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:13591369.

    • Search Google Scholar
    • Export Citation
  • 178.

    Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother 2006;40:19661973.

    • Search Google Scholar
    • Export Citation
  • 179.

    Jacobson SA. Delirium in the elderly. Psychiatr Clin North Am 1997;20:91110.

  • 180.

    Caraceni A, Nanni O, Maltoni M. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer 2000;89:11451149.

    • Search Google Scholar
    • Export Citation
  • 181.

    Kehl KA. Treatment of terminal restlessness: a review of the evidence. J Pain Palliat Care Pharmacother 2004;18:530.

  • 182.

    Weeks JC, Cook EF, O'Day SJ. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:17091714.

    • Search Google Scholar
    • Export Citation
  • 183.

    Smith TJ, Dow LA, Virago EA. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol 2011;9:7986.

    • Search Google Scholar
    • Export Citation
  • 184.

    Wright AA, Zhang B, Ray A. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008;300:16651673.

    • Search Google Scholar
    • Export Citation
  • 185.

    Smith TJ, Swisher K. Telling the truth about terminal cancer. JAMA 1998;279:17461748.

  • 186.

    Mack JW, Wolfe J, Cook EF. Hope and prognostic disclosure. J Clin Oncol 2007;25:56365642.

  • 187.

    Liu PH, Landrum MB, Weeks JC. Physicians' propensity to discuss prognosis is associated with patients' awareness of prognosis for metastatic cancers. J Palliat Med 2014;17:673682.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1369 871 59
PDF Downloads 286 159 20
EPUB Downloads 0 0 0